Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Breast Neoplasms 45Sarcoma 33Lymphoma, Large B-Cell, Diffuse 32Neoplasms 25Lymphoma 20Lymphoma, Non-Hodgkin 19Ovarian Neoplasms 17Lymphoma, Follicular 17Neoplasm Metastasis 12Triple Negative Breast Neoplasms 11Lymphoma, B-Cell 11Endometrial Neoplasms 11Recurrence 10Carcinoma, Hepatocellular 8Hodgkin Disease 7Lymphoma, T-Cell, Peripheral 6Hematologic Diseases 6Sarcoma, Kaposi 5Lymphoma, Mantle-Cell 5Leiomyosarcoma 5HIV Infections 5Acquired Immunodeficiency Syndrome 5Multiple Myeloma 4Liposarcoma 4Small Cell Lung Carcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Lymphoma, B-Cell, Marginal Zone 3Liver Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Fallopian Tube Neoplasms 3

Interventions

tumor necrosis factor-alpha, CNGRC fusion protein, human 2liposomal doxorubicin 2durvalumab 2Nivolumab 2Gemcitabine 2Doxorubicin 2Dexamethasone 2tremelimumab 1tivozanib 1ricolinostat 1pomalidomide 1nilotinib 1capivasertib 1Zoledronic Acid 1Vitamin D 1Taxes 1Oxaliplatin 1Leucovorin 1Lenalidomide 1Fulvestrant 1Folfox protocol 1Fluorouracil 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1Cisplatin 1Calcium 1Bortezomib 1AZD 6244 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Disease Progression × Doxorubicin × Clear all
NCT03804866 2019-01-15

NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)

AGC Biologics S.p.A.

Phase 2 Completed
14 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms, Disease Progression

NCT01358071 2018-09-27

NGR018

AGC Biologics S.p.A.

Phase 2 Completed
119 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡